MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    A homozygous loss-of-function mutation in DNAJA3 causes hereditary motor and sensory neuropathy with spastic paraplegia (HMSN type V)

    T. Kawarai, R. Miyamoto, Y. Kuroda, M. Omoto, M. Ueyama, N. Murakami, T. Furukawa, R. Oki, A. Mori, Y. Osaki, C. Banzrai, H. Nodera, A. Orlacchio, A. Hashiguchi, Y. Higuchi, H. Takashima, T. Kanda, Y. Izumi, Y. Nagai, T. Mitsui, R. Kaji (Tokushima, Japan)

    Objective: To identify a genetic cause for hereditary motor and sensory neuropathy with spastic paraplegia (HMSN type V). Background: Hereditary spastic paraplegia (HSP) constitutes a…
  • 2016 International Congress

    A phase 3, placebo-controlled study with an open-label extension: Sustained incobotulinumtoxinA efficacy in upper-limb post-stroke spasticity over 48 weeks

    P. Kanovský, A. Brashear, E.P. Elovic, M.C. Munin, A. Hanschmann, R. Hiersemenzel, C. Marciniak (Olomouc, Czech Republic)

    Objective: To assess the efficacy and safety of incobotulinumtoxinA for upper-limb post-stroke spasticity. Background: Botulinum toxin injections are a recommended therapy for limb spasticity. We…
  • 2016 International Congress

    Safety and efficacy of escalating doses of incobotulinumtoxinA (400-800U): Increasing improvements in disability due to multifocal upper- and lower-limb spasticity

    J. Wissel, D. Bensmail, B. Rubin, A. Scheschonka, O. Simon, D.M. Simpson (Berlin, Germany)

    Objective: To assess the safety and efficacy of escalating incobotulinumtoxinA doses (400-800U) in patients with spasticity. Background: Botulinum toxin treatment at higher doses than currently…
  • 2016 International Congress

    SPAsticity in PractiCE (SPACE) – An international, observational study of botulinum toxin type A in spasticity

    J. Wissel, J. Harriss, O. Simon, K. Sternberg, N. Roche, C. Cantú-Brito, S. Khatkova, P. Säterö (Berlin, Germany)

    Objective: To collect real-world routine clinical practice data on effectiveness, safety, and quality of life (QoL) for botulinum toxin type A (BoNT-A) treatment of focal…
  • 2016 International Congress

    Muscle selection patterns for injection of onabotulinumtoxinA in adult patients with post-stroke lower-limb spasticity influence outcome: Results from a double-blind, placebo-controlled phase 3 clinical trial

    T.H. Wein, A. Esquenazi, A.B. Ward, C. Geis, C. Liu, R. Dimitrova (Montreal, QC, Canada)

    Objective: The objective of this analysis is to identify an optimal muscle selection pattern for onabotulinumtoxinA injection for the treatment of post-stroke lower-limb spasticity (PSLLS).…
  • 2016 International Congress

    Spastic gait and mechanical energy recovery in children with hereditary spastic paraplegia

    V. Maltese, S. Klebe, A. Marzegan, M. Dipaola, J. Volkmann, C.A. Frigo, P. Cavallari, I.U. Isaias (Wuerzburg, Germany)

    Objective: We aimed to address spastic muscle behavior under dynamic conditions in children with hereditary spastic paraplegia (HSP). Background: HSPs are a clinically and genetically…
  • 2016 International Congress

    Hemi-stereotypies symptomatic to aneurysm: Differential diagnosis of tardive dyskinesia

    D. Rebolledo, P.O. Gonzalez, Z. Rebolledo, A.G.S. Fokine Dotsenko (La Magdalena, Toluca de Lerdo, Mexico)

    Objective: Below we present the case of a hemi-stereotypies symptomatic to aneurysm of the middle cerebral artery presented in mass effect on the subthalamic nucleus…
  • 2016 International Congress

    A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome

    J. Jankovic, J. Jimenez-Shahed, C. Budman, B. Coffey, T.K. Murphy, D. Shprecher, D. Stamler (Houston, TX, USA)

    Objective: This study explored the safety, tolerability and preliminary efficacy of SD-809 (deutetrabenazine) in adolescents with moderate to severe tics associated with Tourette syndrome (TS).…
  • 2016 International Congress

    Longitudinal follow-up of the association of tic disorders with poor academic performance

    E. Cubo, C. Gonzalez-Deza, V. Ausin, V. Delgado, S. Saez, X.R. Garcia-Soto, S. Calvo, J. Cordero, J.M. Trejo, J. Macarron, K. Kompoliti (Burgos, Spain)

    Objective: To analyze whether the presence of a tic disorder is associated with an increased risk for developing poor academic performance overtime. Background: Tic disorders…
  • 2016 International Congress

    The temporal relationship between premonitory sensations and tics compared to obsessions

    V.C. Brandt, C. Beck, J. Hermanns, T. Bäumer, B. Zurowski, S. Anders, A. Münchau (Lübeck, Germany)

    Objective: Investigating the real-time relationship between premonitory urges and tics as compared to the urge to blink in healthy controls and the urge to execute…
  • « Previous Page
  • 1
  • …
  • 1617
  • 1618
  • 1619
  • 1620
  • 1621
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley